Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
Researchers presented findings from CAPTURE, a prospective trial of COVID-19 vaccine or SARS-CoV-2-induced immunity in cancer patients.
The phase 3 CheckMate 651 trial showed prolonged overall survival and durable responses in specific subsets of patients.
Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.
Avelumab plus cetuximab and radiotherapy did not improve progression-free survival over standard care in cisplatin-fit or -unfit patients.
The duration of response was more than 3 years in 68% of patients.
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Responses in cancer patients were noninferior to responses in patients without cancer.
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
The rate of perioperative distant metastases was significantly lower with CapeOx than with CRT.
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.
At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.